世界各国のリアルタイムなデータ・インテリジェンスで皆様をお手伝い
 PD-1およびPDL-1阻害剤 - 世界市場シェアとランキング、全体売上高と需要予測 2025-2031PD-1 and PDL-1 Inhibitors - Global Market Share and Ranking, Overall Sales and Demand Forecast 2025-2031 PD-1阻害剤とPDL-1阻害剤の世界市場は、2024年には4億5,430万米ドル規模と推定され、2031年には7億2,470万米ドルに再調整され、予測期間2025-2031年の年平均成長率は7.0%と予測されている。 PD-1阻害剤とPD-L1阻... もっと見る
※当ページの内容はウェブ更新時の情報です。 
サマリーPD-1阻害剤とPDL-1阻害剤の世界市場は、2024年には4億5,430万米ドル規模と推定され、2031年には7億2,470万米ドルに再調整され、予測期間2025-2031年の年平均成長率は7.0%と予測されている。PD-1阻害剤とPD-L1阻害剤は、がん治療のために開発されているチェックポイント阻害剤の一群である。PD-1とPD-L1はいずれも細胞表面に存在するタンパク質である。これらのような免疫チェックポイント阻害剤は、いくつかのタイプのがんに対する最前線の治療薬として台頭してきている。 北米が最大の消費地であり、2019年の消費市場シェアは60.40%近くである。北米に次いで欧州が2番目に大きな消費地で、消費市場シェアは20.66%である。メルク、ブリストル・マイヤーズ スクイブ、ロシュ、アストラゼネカ、小野薬品工業などが業界のリーダーである。 本レポートは、PD-1およびPDL-1阻害剤の世界市場を包括的に紹介することを目的としており、地域別・国別、タイプ別、用途別のPD-1およびPDL-1阻害剤の分析とともに、総販売量、販売収益、価格、主要企業の市場シェア、ランキングに焦点を当てています。 PD-1およびPDL-1阻害剤の市場規模、推計、予測は、2024年を基準年とし、2020年から2031年までの期間の履歴データおよび予測データとともに、販売数量（Kユニット）および販売収益（百万ドル）で提供されます。定量的および定性的な分析により、読者が事業/成長戦略を策定し、市場競争状況を評価し、現在の市場における自社のポジションを分析し、PD-1およびPDL-1阻害剤に関する十分な情報に基づいたビジネス上の意思決定を行えるよう支援します。 市場区分 企業別 グラクソ・スミスクライン plc ブリストル・マイヤーズ スクイブ社 アーカスバイオサイエンシズ社 アジェナス社 F.ホフマン・ラ・ロシュ社 アストラゼネカPLC ベイジーン社 インサイト社 バイオキャド シストン・ファーマシューティカルズ 小野薬品工業 メルク 上海潤思生物科技有限公司メルク 上海恒隆生物科技有限公司 江蘇恒瑞医薬有限公司 タイプ別 ペムブロリズマブ ニボルマブ アテゾリズマブ デュルバルマブ アベルマブ 用途別セグメント 胃がん 肝臓がん 腎臓がん 膀胱がん 子宮頸がん その他 地域別 北米 米国 カナダ アジア太平洋 中国 日本 韓国 東南アジア インド オーストラリア その他のアジア太平洋地域 ヨーロッパ ドイツ フランス 英国 イタリア オランダ 北欧諸国 その他のヨーロッパ ラテンアメリカ メキシコ ブラジル その他のラテンアメリカ 中東・アフリカ トルコ サウジアラビア アラブ首長国連邦 その他のMEA 各章の概要 第1章： レポートのスコープ、世界の総市場規模（金額、数量、価格）を紹介します。また本章では、市場ダイナミクス、市場の最新動向、市場の推進要因と制限要因、業界メーカーが直面する課題とリスク、業界の関連政策の分析を提供します。 第2章：PD-1およびPDL-1阻害剤メーカーの競争環境、価格、売上高、市場シェア、最新の開発計画、合併・買収情報などを詳細に分析。 第3章：各種市場セグメントをタイプ別に分析し、各市場セグメントの市場規模や発展可能性を網羅し、読者が各市場セグメントにおけるブルーオーシャン市場を見つけやすくします。 第4章：アプリケーション別の様々な市場セグメントの分析を提供し、各市場セグメントの市場規模と発展可能性をカバーし、読者が異なる下流市場のブルーオーシャン市場を見つけるのに役立ちます。 第5章：地域レベルでのPD-1およびPDL-1阻害剤の売上、収益。各地域の市場規模と発展可能性を定量的に分析し、世界各国の市場発展、将来発展見込み、市場空間、市場規模を紹介しています。 第6章 PD-1およびPDL-1阻害剤の国別売上高、収益。各国/地域のタイプ別、用途別のシグメイトデータを提供。 第7章：主要企業のプロフィールを提供し、製品の売上高、収益、価格、粗利益率、製品紹介、最近の開発など、市場における主要企業の基本的な状況を詳細に紹介する。 第8章：産業の上流と下流を含む産業チェーンの分析。 第9章：結論 目次1 Market Overview1.1 PD-1 and PDL-1 Inhibitors Product Introduction 1.2 Global PD-1 and PDL-1 Inhibitors Market Size Forecast 1.2.1 Global PD-1 and PDL-1 Inhibitors Sales Value (2020-2031) 1.2.2 Global PD-1 and PDL-1 Inhibitors Sales Volume (2020-2031) 1.2.3 Global PD-1 and PDL-1 Inhibitors Sales Price (2020-2031) 1.3 PD-1 and PDL-1 Inhibitors Market Trends & Drivers 1.3.1 PD-1 and PDL-1 Inhibitors Industry Trends 1.3.2 PD-1 and PDL-1 Inhibitors Market Drivers & Opportunity 1.3.3 PD-1 and PDL-1 Inhibitors Market Challenges 1.3.4 PD-1 and PDL-1 Inhibitors Market Restraints 1.4 Assumptions and Limitations 1.5 Study Objectives 1.6 Years Considered 2 Competitive Analysis by Company 2.1 Global PD-1 and PDL-1 Inhibitors Players Revenue Ranking (2024) 2.2 Global PD-1 and PDL-1 Inhibitors Revenue by Company (2020-2025) 2.3 Global PD-1 and PDL-1 Inhibitors Players Sales Volume Ranking (2024) 2.4 Global PD-1 and PDL-1 Inhibitors Sales Volume by Company Players (2020-2025) 2.5 Global PD-1 and PDL-1 Inhibitors Average Price by Company (2020-2025) 2.6 Key Manufacturers PD-1 and PDL-1 Inhibitors Manufacturing Base and Headquarters 2.7 Key Manufacturers PD-1 and PDL-1 Inhibitors Product Offered 2.8 Key Manufacturers Time to Begin Mass Production of PD-1 and PDL-1 Inhibitors 2.9 PD-1 and PDL-1 Inhibitors Market Competitive Analysis 2.9.1 PD-1 and PDL-1 Inhibitors Market Concentration Rate (2020-2025) 2.9.2 Global 5 and 10 Largest Manufacturers by PD-1 and PDL-1 Inhibitors Revenue in 2024 2.9.3 Global Top Manufacturers by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in PD-1 and PDL-1 Inhibitors as of 2024) 2.10 Mergers & Acquisitions, Expansion 3 Segmentation by Type 3.1 Introduction by Type 3.1.1 Pembrolizumab 3.1.2 Nivolumab 3.1.3 Atezolizumab 3.1.4 Durvalumab 3.1.5 Avelumab 3.2 Global PD-1 and PDL-1 Inhibitors Sales Value by Type 3.2.1 Global PD-1 and PDL-1 Inhibitors Sales Value by Type (2020 VS 2024 VS 2031) 3.2.2 Global PD-1 and PDL-1 Inhibitors Sales Value, by Type (2020-2031) 3.2.3 Global PD-1 and PDL-1 Inhibitors Sales Value, by Type (%) (2020-2031) 3.3 Global PD-1 and PDL-1 Inhibitors Sales Volume by Type 3.3.1 Global PD-1 and PDL-1 Inhibitors Sales Volume by Type (2020 VS 2024 VS 2031) 3.3.2 Global PD-1 and PDL-1 Inhibitors Sales Volume, by Type (2020-2031) 3.3.3 Global PD-1 and PDL-1 Inhibitors Sales Volume, by Type (%) (2020-2031) 3.4 Global PD-1 and PDL-1 Inhibitors Average Price by Type (2020-2031) 4 Segmentation by Application 4.1 Introduction by Application 4.1.1 Stomach Cancer 4.1.2 Liver Cancer 4.1.3 Kidney Ccancer 4.1.4 Bladder Cancer 4.1.5 Cervical Cancer 4.1.6 Other 4.2 Global PD-1 and PDL-1 Inhibitors Sales Value by Application 4.2.1 Global PD-1 and PDL-1 Inhibitors Sales Value by Application (2020 VS 2024 VS 2031) 4.2.2 Global PD-1 and PDL-1 Inhibitors Sales Value, by Application (2020-2031) 4.2.3 Global PD-1 and PDL-1 Inhibitors Sales Value, by Application (%) (2020-2031) 4.3 Global PD-1 and PDL-1 Inhibitors Sales Volume by Application 4.3.1 Global PD-1 and PDL-1 Inhibitors Sales Volume by Application (2020 VS 2024 VS 2031) 4.3.2 Global PD-1 and PDL-1 Inhibitors Sales Volume, by Application (2020-2031) 4.3.3 Global PD-1 and PDL-1 Inhibitors Sales Volume, by Application (%) (2020-2031) 4.4 Global PD-1 and PDL-1 Inhibitors Average Price by Application (2020-2031) 5 Segmentation by Region 5.1 Global PD-1 and PDL-1 Inhibitors Sales Value by Region 5.1.1 Global PD-1 and PDL-1 Inhibitors Sales Value by Region: 2020 VS 2024 VS 2031 5.1.2 Global PD-1 and PDL-1 Inhibitors Sales Value by Region (2020-2025) 5.1.3 Global PD-1 and PDL-1 Inhibitors Sales Value by Region (2026-2031) 5.1.4 Global PD-1 and PDL-1 Inhibitors Sales Value by Region (%), (2020-2031) 5.2 Global PD-1 and PDL-1 Inhibitors Sales Volume by Region 5.2.1 Global PD-1 and PDL-1 Inhibitors Sales Volume by Region: 2020 VS 2024 VS 2031 5.2.2 Global PD-1 and PDL-1 Inhibitors Sales Volume by Region (2020-2025) 5.2.3 Global PD-1 and PDL-1 Inhibitors Sales Volume by Region (2026-2031) 5.2.4 Global PD-1 and PDL-1 Inhibitors Sales Volume by Region (%), (2020-2031) 5.3 Global PD-1 and PDL-1 Inhibitors Average Price by Region (2020-2031) 5.4 North America 5.4.1 North America PD-1 and PDL-1 Inhibitors Sales Value, 2020-2031 5.4.2 North America PD-1 and PDL-1 Inhibitors Sales Value by Country (%), 2024 VS 2031 5.5 Europe 5.5.1 Europe PD-1 and PDL-1 Inhibitors Sales Value, 2020-2031 5.5.2 Europe PD-1 and PDL-1 Inhibitors Sales Value by Country (%), 2024 VS 2031 5.6 Asia Pacific 5.6.1 Asia Pacific PD-1 and PDL-1 Inhibitors Sales Value, 2020-2031 5.6.2 Asia Pacific PD-1 and PDL-1 Inhibitors Sales Value by Region (%), 2024 VS 2031 5.7 South America 5.7.1 South America PD-1 and PDL-1 Inhibitors Sales Value, 2020-2031 5.7.2 South America PD-1 and PDL-1 Inhibitors Sales Value by Country (%), 2024 VS 2031 5.8 Middle East & Africa 5.8.1 Middle East & Africa PD-1 and PDL-1 Inhibitors Sales Value, 2020-2031 5.8.2 Middle East & Africa PD-1 and PDL-1 Inhibitors Sales Value by Country (%), 2024 VS 2031 6 Segmentation by Key Countries/Regions 6.1 Key Countries/Regions PD-1 and PDL-1 Inhibitors Sales Value Growth Trends, 2020 VS 2024 VS 2031 6.2 Key Countries/Regions PD-1 and PDL-1 Inhibitors Sales Value 6.2.1 Key Countries/Regions PD-1 and PDL-1 Inhibitors Sales Value, 2020-2031 6.2.2 Key Countries/Regions PD-1 and PDL-1 Inhibitors Sales Volume, 2020-2031 6.3 United States 6.3.1 United States PD-1 and PDL-1 Inhibitors Sales Value, 2020-2031 6.3.2 United States PD-1 and PDL-1 Inhibitors Sales Value by Type (%), 2024 VS 2031 6.3.3 United States PD-1 and PDL-1 Inhibitors Sales Value by Application, 2024 VS 2031 6.4 Europe 6.4.1 Europe PD-1 and PDL-1 Inhibitors Sales Value, 2020-2031 6.4.2 Europe PD-1 and PDL-1 Inhibitors Sales Value by Type (%), 2024 VS 2031 6.4.3 Europe PD-1 and PDL-1 Inhibitors Sales Value by Application, 2024 VS 2031 6.5 China 6.5.1 China PD-1 and PDL-1 Inhibitors Sales Value, 2020-2031 6.5.2 China PD-1 and PDL-1 Inhibitors Sales Value by Type (%), 2024 VS 2031 6.5.3 China PD-1 and PDL-1 Inhibitors Sales Value by Application, 2024 VS 2031 6.6 Japan 6.6.1 Japan PD-1 and PDL-1 Inhibitors Sales Value, 2020-2031 6.6.2 Japan PD-1 and PDL-1 Inhibitors Sales Value by Type (%), 2024 VS 2031 6.6.3 Japan PD-1 and PDL-1 Inhibitors Sales Value by Application, 2024 VS 2031 6.7 South Korea 6.7.1 South Korea PD-1 and PDL-1 Inhibitors Sales Value, 2020-2031 6.7.2 South Korea PD-1 and PDL-1 Inhibitors Sales Value by Type (%), 2024 VS 2031 6.7.3 South Korea PD-1 and PDL-1 Inhibitors Sales Value by Application, 2024 VS 2031 6.8 Southeast Asia 6.8.1 Southeast Asia PD-1 and PDL-1 Inhibitors Sales Value, 2020-2031 6.8.2 Southeast Asia PD-1 and PDL-1 Inhibitors Sales Value by Type (%), 2024 VS 2031 6.8.3 Southeast Asia PD-1 and PDL-1 Inhibitors Sales Value by Application, 2024 VS 2031 6.9 India 6.9.1 India PD-1 and PDL-1 Inhibitors Sales Value, 2020-2031 6.9.2 India PD-1 and PDL-1 Inhibitors Sales Value by Type (%), 2024 VS 2031 6.9.3 India PD-1 and PDL-1 Inhibitors Sales Value by Application, 2024 VS 2031 7 Company Profiles 7.1 GlaxoSmithKline plc 7.1.1 GlaxoSmithKline plc Company Information 7.1.2 GlaxoSmithKline plc Introduction and Business Overview 7.1.3 GlaxoSmithKline plc PD-1 and PDL-1 Inhibitors Sales, Revenue, Price and Gross Margin (2020-2025) 7.1.4 GlaxoSmithKline plc PD-1 and PDL-1 Inhibitors Product Offerings 7.1.5 GlaxoSmithKline plc Recent Development 7.2 Bristol-Myers Squibb Company 7.2.1 Bristol-Myers Squibb Company Company Information 7.2.2 Bristol-Myers Squibb Company Introduction and Business Overview 7.2.3 Bristol-Myers Squibb Company PD-1 and PDL-1 Inhibitors Sales, Revenue, Price and Gross Margin (2020-2025) 7.2.4 Bristol-Myers Squibb Company PD-1 and PDL-1 Inhibitors Product Offerings 7.2.5 Bristol-Myers Squibb Company Recent Development 7.3 Arcus Biosciences, Inc. 7.3.1 Arcus Biosciences, Inc. Company Information 7.3.2 Arcus Biosciences, Inc. Introduction and Business Overview 7.3.3 Arcus Biosciences, Inc. PD-1 and PDL-1 Inhibitors Sales, Revenue, Price and Gross Margin (2020-2025) 7.3.4 Arcus Biosciences, Inc. PD-1 and PDL-1 Inhibitors Product Offerings 7.3.5 Arcus Biosciences, Inc. Recent Development 7.4 Agenus Inc 7.4.1 Agenus Inc Company Information 7.4.2 Agenus Inc Introduction and Business Overview 7.4.3 Agenus Inc PD-1 and PDL-1 Inhibitors Sales, Revenue, Price and Gross Margin (2020-2025) 7.4.4 Agenus Inc PD-1 and PDL-1 Inhibitors Product Offerings 7.4.5 Agenus Inc Recent Development 7.5 F. Hoffmann-La Roche Ltd 7.5.1 F. Hoffmann-La Roche Ltd Company Information 7.5.2 F. Hoffmann-La Roche Ltd Introduction and Business Overview 7.5.3 F. Hoffmann-La Roche Ltd PD-1 and PDL-1 Inhibitors Sales, Revenue, Price and Gross Margin (2020-2025) 7.5.4 F. Hoffmann-La Roche Ltd PD-1 and PDL-1 Inhibitors Product Offerings 7.5.5 F. Hoffmann-La Roche Ltd Recent Development 7.6 Astra Zeneca PLC 7.6.1 Astra Zeneca PLC Company Information 7.6.2 Astra Zeneca PLC Introduction and Business Overview 7.6.3 Astra Zeneca PLC PD-1 and PDL-1 Inhibitors Sales, Revenue, Price and Gross Margin (2020-2025) 7.6.4 Astra Zeneca PLC PD-1 and PDL-1 Inhibitors Product Offerings 7.6.5 Astra Zeneca PLC Recent Development 7.7 Beigene Ltd 7.7.1 Beigene Ltd Company Information 7.7.2 Beigene Ltd Introduction and Business Overview 7.7.3 Beigene Ltd PD-1 and PDL-1 Inhibitors Sales, Revenue, Price and Gross Margin (2020-2025) 7.7.4 Beigene Ltd PD-1 and PDL-1 Inhibitors Product Offerings 7.7.5 Beigene Ltd Recent Development 7.8 Incyte Corporation 7.8.1 Incyte Corporation Company Information 7.8.2 Incyte Corporation Introduction and Business Overview 7.8.3 Incyte Corporation PD-1 and PDL-1 Inhibitors Sales, Revenue, Price and Gross Margin (2020-2025) 7.8.4 Incyte Corporation PD-1 and PDL-1 Inhibitors Product Offerings 7.8.5 Incyte Corporation Recent Development 7.9 Biocad 7.9.1 Biocad Company Information 7.9.2 Biocad Introduction and Business Overview 7.9.3 Biocad PD-1 and PDL-1 Inhibitors Sales, Revenue, Price and Gross Margin (2020-2025) 7.9.4 Biocad PD-1 and PDL-1 Inhibitors Product Offerings 7.9.5 Biocad Recent Development 7.10 CStone Pharmaceuticals 7.10.1 CStone Pharmaceuticals Company Information 7.10.2 CStone Pharmaceuticals Introduction and Business Overview 7.10.3 CStone Pharmaceuticals PD-1 and PDL-1 Inhibitors Sales, Revenue, Price and Gross Margin (2020-2025) 7.10.4 CStone Pharmaceuticals PD-1 and PDL-1 Inhibitors Product Offerings 7.10.5 CStone Pharmaceuticals Recent Development 7.11 Ono Pharmaceutical 7.11.1 Ono Pharmaceutical Company Information 7.11.2 Ono Pharmaceutical Introduction and Business Overview 7.11.3 Ono Pharmaceutical PD-1 and PDL-1 Inhibitors Sales, Revenue, Price and Gross Margin (2020-2025) 7.11.4 Ono Pharmaceutical PD-1 and PDL-1 Inhibitors Product Offerings 7.11.5 Ono Pharmaceutical Recent Development 7.12 Merck 7.12.1 Merck Company Information 7.12.2 Merck Introduction and Business Overview 7.12.3 Merck PD-1 and PDL-1 Inhibitors Sales, Revenue, Price and Gross Margin (2020-2025) 7.12.4 Merck PD-1 and PDL-1 Inhibitors Product Offerings 7.12.5 Merck Recent Development 7.13 Shanghai Junshi Bioscience Co. Ltd 7.13.1 Shanghai Junshi Bioscience Co. Ltd Company Information 7.13.2 Shanghai Junshi Bioscience Co. Ltd Introduction and Business Overview 7.13.3 Shanghai Junshi Bioscience Co. Ltd PD-1 and PDL-1 Inhibitors Sales, Revenue, Price and Gross Margin (2020-2025) 7.13.4 Shanghai Junshi Bioscience Co. Ltd PD-1 and PDL-1 Inhibitors Product Offerings 7.13.5 Shanghai Junshi Bioscience Co. Ltd Recent Development 7.14 Shanghai Henlius Biotech, Inc. 7.14.1 Shanghai Henlius Biotech, Inc. Company Information 7.14.2 Shanghai Henlius Biotech, Inc. Introduction and Business Overview 7.14.3 Shanghai Henlius Biotech, Inc. PD-1 and PDL-1 Inhibitors Sales, Revenue, Price and Gross Margin (2020-2025) 7.14.4 Shanghai Henlius Biotech, Inc. PD-1 and PDL-1 Inhibitors Product Offerings 7.14.5 Shanghai Henlius Biotech, Inc. Recent Development 7.15 Jiangsu HengRui Medicine Co., Ltd. 7.15.1 Jiangsu HengRui Medicine Co., Ltd. Company Information 7.15.2 Jiangsu HengRui Medicine Co., Ltd. Introduction and Business Overview 7.15.3 Jiangsu HengRui Medicine Co., Ltd. PD-1 and PDL-1 Inhibitors Sales, Revenue, Price and Gross Margin (2020-2025) 7.15.4 Jiangsu HengRui Medicine Co., Ltd. PD-1 and PDL-1 Inhibitors Product Offerings 7.15.5 Jiangsu HengRui Medicine Co., Ltd. Recent Development 8 Industry Chain Analysis 8.1 PD-1 and PDL-1 Inhibitors Industrial Chain 8.2 PD-1 and PDL-1 Inhibitors Upstream Analysis 8.2.1 Key Raw Materials 8.2.2 Raw Materials Key Suppliers 8.2.3 Manufacturing Cost Structure 8.3 Midstream Analysis 8.4 Downstream Analysis (Customers Analysis) 8.5 Sales Model and Sales Channels 8.5.1 PD-1 and PDL-1 Inhibitors Sales Model 8.5.2 Sales Channel 8.5.3 PD-1 and PDL-1 Inhibitors Distributors 9 Research Findings and Conclusion 10 Appendix 10.1 Research Methodology 10.1.1 Methodology/Research Approach 10.1.1.1 Research Programs/Design 10.1.1.2 Market Size Estimation 10.1.1.3 Market Breakdown and Data Triangulation 10.1.2 Data Source 10.1.2.1 Secondary Sources 10.1.2.2 Primary Sources 10.2 Author Details 10.3 Disclaimer
SummaryThe global market for PD-1 and PDL-1 Inhibitors was estimated to be worth US$ 45430 million in 2024 and is forecast to a readjusted size of US$ 72470 million by 2031 with a CAGR of 7.0% during the forecast period 2025-2031. Table of Contents1 Market Overview1.1 PD-1 and PDL-1 Inhibitors Product Introduction 1.2 Global PD-1 and PDL-1 Inhibitors Market Size Forecast 1.2.1 Global PD-1 and PDL-1 Inhibitors Sales Value (2020-2031) 1.2.2 Global PD-1 and PDL-1 Inhibitors Sales Volume (2020-2031) 1.2.3 Global PD-1 and PDL-1 Inhibitors Sales Price (2020-2031) 1.3 PD-1 and PDL-1 Inhibitors Market Trends & Drivers 1.3.1 PD-1 and PDL-1 Inhibitors Industry Trends 1.3.2 PD-1 and PDL-1 Inhibitors Market Drivers & Opportunity 1.3.3 PD-1 and PDL-1 Inhibitors Market Challenges 1.3.4 PD-1 and PDL-1 Inhibitors Market Restraints 1.4 Assumptions and Limitations 1.5 Study Objectives 1.6 Years Considered 2 Competitive Analysis by Company 2.1 Global PD-1 and PDL-1 Inhibitors Players Revenue Ranking (2024) 2.2 Global PD-1 and PDL-1 Inhibitors Revenue by Company (2020-2025) 2.3 Global PD-1 and PDL-1 Inhibitors Players Sales Volume Ranking (2024) 2.4 Global PD-1 and PDL-1 Inhibitors Sales Volume by Company Players (2020-2025) 2.5 Global PD-1 and PDL-1 Inhibitors Average Price by Company (2020-2025) 2.6 Key Manufacturers PD-1 and PDL-1 Inhibitors Manufacturing Base and Headquarters 2.7 Key Manufacturers PD-1 and PDL-1 Inhibitors Product Offered 2.8 Key Manufacturers Time to Begin Mass Production of PD-1 and PDL-1 Inhibitors 2.9 PD-1 and PDL-1 Inhibitors Market Competitive Analysis 2.9.1 PD-1 and PDL-1 Inhibitors Market Concentration Rate (2020-2025) 2.9.2 Global 5 and 10 Largest Manufacturers by PD-1 and PDL-1 Inhibitors Revenue in 2024 2.9.3 Global Top Manufacturers by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in PD-1 and PDL-1 Inhibitors as of 2024) 2.10 Mergers & Acquisitions, Expansion 3 Segmentation by Type 3.1 Introduction by Type 3.1.1 Pembrolizumab 3.1.2 Nivolumab 3.1.3 Atezolizumab 3.1.4 Durvalumab 3.1.5 Avelumab 3.2 Global PD-1 and PDL-1 Inhibitors Sales Value by Type 3.2.1 Global PD-1 and PDL-1 Inhibitors Sales Value by Type (2020 VS 2024 VS 2031) 3.2.2 Global PD-1 and PDL-1 Inhibitors Sales Value, by Type (2020-2031) 3.2.3 Global PD-1 and PDL-1 Inhibitors Sales Value, by Type (%) (2020-2031) 3.3 Global PD-1 and PDL-1 Inhibitors Sales Volume by Type 3.3.1 Global PD-1 and PDL-1 Inhibitors Sales Volume by Type (2020 VS 2024 VS 2031) 3.3.2 Global PD-1 and PDL-1 Inhibitors Sales Volume, by Type (2020-2031) 3.3.3 Global PD-1 and PDL-1 Inhibitors Sales Volume, by Type (%) (2020-2031) 3.4 Global PD-1 and PDL-1 Inhibitors Average Price by Type (2020-2031) 4 Segmentation by Application 4.1 Introduction by Application 4.1.1 Stomach Cancer 4.1.2 Liver Cancer 4.1.3 Kidney Ccancer 4.1.4 Bladder Cancer 4.1.5 Cervical Cancer 4.1.6 Other 4.2 Global PD-1 and PDL-1 Inhibitors Sales Value by Application 4.2.1 Global PD-1 and PDL-1 Inhibitors Sales Value by Application (2020 VS 2024 VS 2031) 4.2.2 Global PD-1 and PDL-1 Inhibitors Sales Value, by Application (2020-2031) 4.2.3 Global PD-1 and PDL-1 Inhibitors Sales Value, by Application (%) (2020-2031) 4.3 Global PD-1 and PDL-1 Inhibitors Sales Volume by Application 4.3.1 Global PD-1 and PDL-1 Inhibitors Sales Volume by Application (2020 VS 2024 VS 2031) 4.3.2 Global PD-1 and PDL-1 Inhibitors Sales Volume, by Application (2020-2031) 4.3.3 Global PD-1 and PDL-1 Inhibitors Sales Volume, by Application (%) (2020-2031) 4.4 Global PD-1 and PDL-1 Inhibitors Average Price by Application (2020-2031) 5 Segmentation by Region 5.1 Global PD-1 and PDL-1 Inhibitors Sales Value by Region 5.1.1 Global PD-1 and PDL-1 Inhibitors Sales Value by Region: 2020 VS 2024 VS 2031 5.1.2 Global PD-1 and PDL-1 Inhibitors Sales Value by Region (2020-2025) 5.1.3 Global PD-1 and PDL-1 Inhibitors Sales Value by Region (2026-2031) 5.1.4 Global PD-1 and PDL-1 Inhibitors Sales Value by Region (%), (2020-2031) 5.2 Global PD-1 and PDL-1 Inhibitors Sales Volume by Region 5.2.1 Global PD-1 and PDL-1 Inhibitors Sales Volume by Region: 2020 VS 2024 VS 2031 5.2.2 Global PD-1 and PDL-1 Inhibitors Sales Volume by Region (2020-2025) 5.2.3 Global PD-1 and PDL-1 Inhibitors Sales Volume by Region (2026-2031) 5.2.4 Global PD-1 and PDL-1 Inhibitors Sales Volume by Region (%), (2020-2031) 5.3 Global PD-1 and PDL-1 Inhibitors Average Price by Region (2020-2031) 5.4 North America 5.4.1 North America PD-1 and PDL-1 Inhibitors Sales Value, 2020-2031 5.4.2 North America PD-1 and PDL-1 Inhibitors Sales Value by Country (%), 2024 VS 2031 5.5 Europe 5.5.1 Europe PD-1 and PDL-1 Inhibitors Sales Value, 2020-2031 5.5.2 Europe PD-1 and PDL-1 Inhibitors Sales Value by Country (%), 2024 VS 2031 5.6 Asia Pacific 5.6.1 Asia Pacific PD-1 and PDL-1 Inhibitors Sales Value, 2020-2031 5.6.2 Asia Pacific PD-1 and PDL-1 Inhibitors Sales Value by Region (%), 2024 VS 2031 5.7 South America 5.7.1 South America PD-1 and PDL-1 Inhibitors Sales Value, 2020-2031 5.7.2 South America PD-1 and PDL-1 Inhibitors Sales Value by Country (%), 2024 VS 2031 5.8 Middle East & Africa 5.8.1 Middle East & Africa PD-1 and PDL-1 Inhibitors Sales Value, 2020-2031 5.8.2 Middle East & Africa PD-1 and PDL-1 Inhibitors Sales Value by Country (%), 2024 VS 2031 6 Segmentation by Key Countries/Regions 6.1 Key Countries/Regions PD-1 and PDL-1 Inhibitors Sales Value Growth Trends, 2020 VS 2024 VS 2031 6.2 Key Countries/Regions PD-1 and PDL-1 Inhibitors Sales Value 6.2.1 Key Countries/Regions PD-1 and PDL-1 Inhibitors Sales Value, 2020-2031 6.2.2 Key Countries/Regions PD-1 and PDL-1 Inhibitors Sales Volume, 2020-2031 6.3 United States 6.3.1 United States PD-1 and PDL-1 Inhibitors Sales Value, 2020-2031 6.3.2 United States PD-1 and PDL-1 Inhibitors Sales Value by Type (%), 2024 VS 2031 6.3.3 United States PD-1 and PDL-1 Inhibitors Sales Value by Application, 2024 VS 2031 6.4 Europe 6.4.1 Europe PD-1 and PDL-1 Inhibitors Sales Value, 2020-2031 6.4.2 Europe PD-1 and PDL-1 Inhibitors Sales Value by Type (%), 2024 VS 2031 6.4.3 Europe PD-1 and PDL-1 Inhibitors Sales Value by Application, 2024 VS 2031 6.5 China 6.5.1 China PD-1 and PDL-1 Inhibitors Sales Value, 2020-2031 6.5.2 China PD-1 and PDL-1 Inhibitors Sales Value by Type (%), 2024 VS 2031 6.5.3 China PD-1 and PDL-1 Inhibitors Sales Value by Application, 2024 VS 2031 6.6 Japan 6.6.1 Japan PD-1 and PDL-1 Inhibitors Sales Value, 2020-2031 6.6.2 Japan PD-1 and PDL-1 Inhibitors Sales Value by Type (%), 2024 VS 2031 6.6.3 Japan PD-1 and PDL-1 Inhibitors Sales Value by Application, 2024 VS 2031 6.7 South Korea 6.7.1 South Korea PD-1 and PDL-1 Inhibitors Sales Value, 2020-2031 6.7.2 South Korea PD-1 and PDL-1 Inhibitors Sales Value by Type (%), 2024 VS 2031 6.7.3 South Korea PD-1 and PDL-1 Inhibitors Sales Value by Application, 2024 VS 2031 6.8 Southeast Asia 6.8.1 Southeast Asia PD-1 and PDL-1 Inhibitors Sales Value, 2020-2031 6.8.2 Southeast Asia PD-1 and PDL-1 Inhibitors Sales Value by Type (%), 2024 VS 2031 6.8.3 Southeast Asia PD-1 and PDL-1 Inhibitors Sales Value by Application, 2024 VS 2031 6.9 India 6.9.1 India PD-1 and PDL-1 Inhibitors Sales Value, 2020-2031 6.9.2 India PD-1 and PDL-1 Inhibitors Sales Value by Type (%), 2024 VS 2031 6.9.3 India PD-1 and PDL-1 Inhibitors Sales Value by Application, 2024 VS 2031 7 Company Profiles 7.1 GlaxoSmithKline plc 7.1.1 GlaxoSmithKline plc Company Information 7.1.2 GlaxoSmithKline plc Introduction and Business Overview 7.1.3 GlaxoSmithKline plc PD-1 and PDL-1 Inhibitors Sales, Revenue, Price and Gross Margin (2020-2025) 7.1.4 GlaxoSmithKline plc PD-1 and PDL-1 Inhibitors Product Offerings 7.1.5 GlaxoSmithKline plc Recent Development 7.2 Bristol-Myers Squibb Company 7.2.1 Bristol-Myers Squibb Company Company Information 7.2.2 Bristol-Myers Squibb Company Introduction and Business Overview 7.2.3 Bristol-Myers Squibb Company PD-1 and PDL-1 Inhibitors Sales, Revenue, Price and Gross Margin (2020-2025) 7.2.4 Bristol-Myers Squibb Company PD-1 and PDL-1 Inhibitors Product Offerings 7.2.5 Bristol-Myers Squibb Company Recent Development 7.3 Arcus Biosciences, Inc. 7.3.1 Arcus Biosciences, Inc. Company Information 7.3.2 Arcus Biosciences, Inc. Introduction and Business Overview 7.3.3 Arcus Biosciences, Inc. PD-1 and PDL-1 Inhibitors Sales, Revenue, Price and Gross Margin (2020-2025) 7.3.4 Arcus Biosciences, Inc. PD-1 and PDL-1 Inhibitors Product Offerings 7.3.5 Arcus Biosciences, Inc. Recent Development 7.4 Agenus Inc 7.4.1 Agenus Inc Company Information 7.4.2 Agenus Inc Introduction and Business Overview 7.4.3 Agenus Inc PD-1 and PDL-1 Inhibitors Sales, Revenue, Price and Gross Margin (2020-2025) 7.4.4 Agenus Inc PD-1 and PDL-1 Inhibitors Product Offerings 7.4.5 Agenus Inc Recent Development 7.5 F. Hoffmann-La Roche Ltd 7.5.1 F. Hoffmann-La Roche Ltd Company Information 7.5.2 F. Hoffmann-La Roche Ltd Introduction and Business Overview 7.5.3 F. Hoffmann-La Roche Ltd PD-1 and PDL-1 Inhibitors Sales, Revenue, Price and Gross Margin (2020-2025) 7.5.4 F. Hoffmann-La Roche Ltd PD-1 and PDL-1 Inhibitors Product Offerings 7.5.5 F. Hoffmann-La Roche Ltd Recent Development 7.6 Astra Zeneca PLC 7.6.1 Astra Zeneca PLC Company Information 7.6.2 Astra Zeneca PLC Introduction and Business Overview 7.6.3 Astra Zeneca PLC PD-1 and PDL-1 Inhibitors Sales, Revenue, Price and Gross Margin (2020-2025) 7.6.4 Astra Zeneca PLC PD-1 and PDL-1 Inhibitors Product Offerings 7.6.5 Astra Zeneca PLC Recent Development 7.7 Beigene Ltd 7.7.1 Beigene Ltd Company Information 7.7.2 Beigene Ltd Introduction and Business Overview 7.7.3 Beigene Ltd PD-1 and PDL-1 Inhibitors Sales, Revenue, Price and Gross Margin (2020-2025) 7.7.4 Beigene Ltd PD-1 and PDL-1 Inhibitors Product Offerings 7.7.5 Beigene Ltd Recent Development 7.8 Incyte Corporation 7.8.1 Incyte Corporation Company Information 7.8.2 Incyte Corporation Introduction and Business Overview 7.8.3 Incyte Corporation PD-1 and PDL-1 Inhibitors Sales, Revenue, Price and Gross Margin (2020-2025) 7.8.4 Incyte Corporation PD-1 and PDL-1 Inhibitors Product Offerings 7.8.5 Incyte Corporation Recent Development 7.9 Biocad 7.9.1 Biocad Company Information 7.9.2 Biocad Introduction and Business Overview 7.9.3 Biocad PD-1 and PDL-1 Inhibitors Sales, Revenue, Price and Gross Margin (2020-2025) 7.9.4 Biocad PD-1 and PDL-1 Inhibitors Product Offerings 7.9.5 Biocad Recent Development 7.10 CStone Pharmaceuticals 7.10.1 CStone Pharmaceuticals Company Information 7.10.2 CStone Pharmaceuticals Introduction and Business Overview 7.10.3 CStone Pharmaceuticals PD-1 and PDL-1 Inhibitors Sales, Revenue, Price and Gross Margin (2020-2025) 7.10.4 CStone Pharmaceuticals PD-1 and PDL-1 Inhibitors Product Offerings 7.10.5 CStone Pharmaceuticals Recent Development 7.11 Ono Pharmaceutical 7.11.1 Ono Pharmaceutical Company Information 7.11.2 Ono Pharmaceutical Introduction and Business Overview 7.11.3 Ono Pharmaceutical PD-1 and PDL-1 Inhibitors Sales, Revenue, Price and Gross Margin (2020-2025) 7.11.4 Ono Pharmaceutical PD-1 and PDL-1 Inhibitors Product Offerings 7.11.5 Ono Pharmaceutical Recent Development 7.12 Merck 7.12.1 Merck Company Information 7.12.2 Merck Introduction and Business Overview 7.12.3 Merck PD-1 and PDL-1 Inhibitors Sales, Revenue, Price and Gross Margin (2020-2025) 7.12.4 Merck PD-1 and PDL-1 Inhibitors Product Offerings 7.12.5 Merck Recent Development 7.13 Shanghai Junshi Bioscience Co. Ltd 7.13.1 Shanghai Junshi Bioscience Co. Ltd Company Information 7.13.2 Shanghai Junshi Bioscience Co. Ltd Introduction and Business Overview 7.13.3 Shanghai Junshi Bioscience Co. Ltd PD-1 and PDL-1 Inhibitors Sales, Revenue, Price and Gross Margin (2020-2025) 7.13.4 Shanghai Junshi Bioscience Co. Ltd PD-1 and PDL-1 Inhibitors Product Offerings 7.13.5 Shanghai Junshi Bioscience Co. Ltd Recent Development 7.14 Shanghai Henlius Biotech, Inc. 7.14.1 Shanghai Henlius Biotech, Inc. Company Information 7.14.2 Shanghai Henlius Biotech, Inc. Introduction and Business Overview 7.14.3 Shanghai Henlius Biotech, Inc. PD-1 and PDL-1 Inhibitors Sales, Revenue, Price and Gross Margin (2020-2025) 7.14.4 Shanghai Henlius Biotech, Inc. PD-1 and PDL-1 Inhibitors Product Offerings 7.14.5 Shanghai Henlius Biotech, Inc. Recent Development 7.15 Jiangsu HengRui Medicine Co., Ltd. 7.15.1 Jiangsu HengRui Medicine Co., Ltd. Company Information 7.15.2 Jiangsu HengRui Medicine Co., Ltd. Introduction and Business Overview 7.15.3 Jiangsu HengRui Medicine Co., Ltd. PD-1 and PDL-1 Inhibitors Sales, Revenue, Price and Gross Margin (2020-2025) 7.15.4 Jiangsu HengRui Medicine Co., Ltd. PD-1 and PDL-1 Inhibitors Product Offerings 7.15.5 Jiangsu HengRui Medicine Co., Ltd. Recent Development 8 Industry Chain Analysis 8.1 PD-1 and PDL-1 Inhibitors Industrial Chain 8.2 PD-1 and PDL-1 Inhibitors Upstream Analysis 8.2.1 Key Raw Materials 8.2.2 Raw Materials Key Suppliers 8.2.3 Manufacturing Cost Structure 8.3 Midstream Analysis 8.4 Downstream Analysis (Customers Analysis) 8.5 Sales Model and Sales Channels 8.5.1 PD-1 and PDL-1 Inhibitors Sales Model 8.5.2 Sales Channel 8.5.3 PD-1 and PDL-1 Inhibitors Distributors 9 Research Findings and Conclusion 10 Appendix 10.1 Research Methodology 10.1.1 Methodology/Research Approach 10.1.1.1 Research Programs/Design 10.1.1.2 Market Size Estimation 10.1.1.3 Market Breakdown and Data Triangulation 10.1.2 Data Source 10.1.2.1 Secondary Sources 10.1.2.2 Primary Sources 10.2 Author Details 10.3 Disclaimer
ご注文は、お電話またはWEBから承ります。お見積もりの作成もお気軽にご相談ください。本レポートと同分野（医療/ヘルスケア）の最新刊レポート
QYResearch社の医薬・ヘルスケア分野での最新刊レポート
本レポートと同じKEY WORD（inhibitors）の最新刊レポート
よくあるご質問QYResearch社はどのような調査会社ですか?QYリサーチ(QYResearch)は幅広い市場を対象に調査・レポート出版を行う、中国に本社をおく調査会社です。 QYResearchでは年間数百タイトルの調査レポートを出版しています。... もっと見る 調査レポートの納品までの日数はどの程度ですか?在庫のあるものは速納となりますが、平均的には 3-４日と見て下さい。
注文の手続きはどのようになっていますか?1)お客様からの御問い合わせをいただきます。
お支払方法の方法はどのようになっていますか?納品と同時にデータリソース社よりお客様へ請求書（必要に応じて納品書も）を発送いたします。
データリソース社はどのような会社ですか?当社は、世界各国の主要調査会社・レポート出版社と提携し、世界各国の市場調査レポートや技術動向レポートなどを日本国内の企業・公官庁及び教育研究機関に提供しております。
|
